Technical Analysis for AIFF - Firefly Neuroscience, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.01 | 0.84% | 0.03 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.84% | |
| NR7-2 | Range Contraction | 0.84% | |
| Narrow Range Bar | Range Contraction | 0.84% | |
| Stochastic Reached Oversold | Weakness | 0.84% | |
| BB Squeeze Ended | Range Expansion | 0.84% | |
| Oversold Stochastic | Weakness | 0.84% | |
| MACD Bearish Signal Line Cross | Bearish | -2.12% | |
| Bollinger Band Squeeze | Range Contraction | -2.12% | |
| NR7 | Range Contraction | -2.12% | |
| Narrow Range Bar | Range Contraction | -2.12% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 2 hours ago |
| 10 DMA Resistance | about 2 hours ago |
| Up 5% | about 2 hours ago |
| Up 3% | about 2 hours ago |
| Up 2% | about 2 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: Unknown
Firefly Neuroscience, Inc. Description
Firefly is an Artificial Intelligence (“AI”) technology company dedicated to developing groundbreaking neuroscientific solutions that enhance outcomes for patients with mental illnesses and neurological disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA) platform revolutionizes diagnostic and treatment methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has invested approximately $60 million in developing its BNA platform, building a comprehensive database of brain wave tests, securing patent protection, and achieving FDA approval. The Company is now launching the BNA platform commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Classification
Sector: Technology
Industry: Information Technology Services
Keywords: Pharmaceutical Artificial Intelligence FDA Neurological Disorders Dementia Depression Major Depressive Disorder Neurology Attention Deficit Hyperactivity Disorder Amphetamine Methylphenidate Adhd Learning Disabilities Mental Disorder Psychopathology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.9 |
| 52 Week Low | 2.74 |
| Average Volume | 248,758 |
| 200-Day Moving Average | 6.01 |
| 50-Day Moving Average | 3.37 |
| 20-Day Moving Average | 3.22 |
| 10-Day Moving Average | 3.22 |
| Average True Range | 0.42 |
| RSI (14) | 43.18 |
| ADX | 29.7 |
| +DI | 21.95 |
| -DI | 15.15 |
| Chandelier Exit (Long, 3 ATRs) | 3.01 |
| Chandelier Exit (Short, 3 ATRs) | 4.12 |
| Upper Bollinger Bands | 3.60 |
| Lower Bollinger Band | 2.83 |
| Percent B (%b) | 0.2 |
| BandWidth | 24.20 |
| MACD Line | -0.10 |
| MACD Signal Line | -0.10 |
| MACD Histogram | -0.0088 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.28 | ||||
| Resistance 3 (R3) | 3.30 | 3.21 | 3.23 | ||
| Resistance 2 (R2) | 3.21 | 3.14 | 3.20 | 3.21 | |
| Resistance 1 (R1) | 3.10 | 3.09 | 3.05 | 3.08 | 3.20 |
| Pivot Point | 3.01 | 3.01 | 2.99 | 3.00 | 3.01 |
| Support 1 (S1) | 2.90 | 2.94 | 2.86 | 2.88 | 2.76 |
| Support 2 (S2) | 2.81 | 2.89 | 2.81 | 2.75 | |
| Support 3 (S3) | 2.70 | 2.81 | 2.73 | ||
| Support 4 (S4) | 2.68 |
